Non-Small Cell Lung Cancer
Report summarizes non-small cell lung cancer study findings from Cleveland Clinic
Published in Hospital Law Weekly, July 10th, 2008
According to a study from the United States, "The aim of this study was to evaluate the safety and tolerability of escalating doses of flavopiridol/paclitaxel/carboplatin in patients with advanced-stage non-small-cell lung cancer (NSCLC) as well as the pharmacokinetics and activity of flavopiridol when used in combination with paclitaxel/carboplatin. Eligible patients aged 18-75 years with previously untreated stage IIIB/IV NSCLC received paclitaxel 175 mg/m(2) over 3 hours followed by carboplatin area under the curve (AUC) 5 over I hour and flavopiridol 30-85 mg/m(2) over 24 hours every 3 weeks for 3 cycles."
"Eighteen patients were enrolled at 4 sites in the United...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
Source: Hospital Law Weekly (2008-07-10)
More Articles from Hospital Law Weekly
- Ballard Spahr Andrews & Ingersoll, LLP
Ballard Acquires Atlanta IP Group - Business of Birth International
Controversies in Childbirth Conference Draws Broad Interest Across Medical Professions, Across the U.S., and Across the Atlantic - Drug Resistance
Federal Action Needed to Fill Antibiotic Pipeline, Says the Alliance for the Prudent Use of Antibiotics - Eric Drew
Credit Card Companies Fueling Healthcare Associated Identity Theft (HAIT) Crimes - Health Insurance
Potential Blues Merger Poses Concern for Area Health Systems - Heart Disease
Appellate Court Rules That $2.7 Million Heart Transplant Verdict Should Stand - More from this issue of Hospital Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
